The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance

被引：23
作者：
Ghazimoradi, Mohammad H. [1 ]
Babashah, Sadegh [1 ]
机构：
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
breast cancer; circRNA; miRNA; drug resistance; oncogenes; tumor suppressors; CIRCULAR RNA; PACLITAXEL RESISTANCE; MECHANISMS; OXALIPLATIN; CONTRIBUTES; KNOCKDOWN; TAMOXIFEN;
D O I：
10.3389/fonc.2022.966083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multidrug resistance is one of the major obstacles in the treatment of cancers. This undesirable feature increases the mortality rate of cancers, including breast cancer. Circular RNA (CircRNA)/microRNA (miRNA)/messenger RNA (mRNA) is one of the important axes with major roles in the promotion and resistance of breast cancer. This heterogeneous pathway includes mRNA of oncogenes and tumor suppressors, which are controlled by miRNAs and CircRNAs. Unfortunately, this network could be easily deregulated, resulting in drug resistance and tumor development. Therefore, understanding these dysregulations may thus help to identify effective therapeutic targets. On this basis, we try to review the latest findings in the field, which could help us to better comprehend this significant axis in breast cancer.
引用
收藏
页数：9
相关论文
共 72 条
  • [1] Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes - Clinical and pharmacokinetic data
    Airoldi, Mario
    Cattel, Luigi
    Passera, Roberto
    Pedani, Fulvia
    Delprino, Laura
    Micari, Caterina
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (05): : 490 - 494
  • [2] Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance
    Al-malky, Hamdan S.
    Al Harthi, Sameer E.
    Osman, Abdel-Moneim M.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 434 - 444
  • [3] What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg
    Alexa-Stratulat, Teodora
    Pesic, Milica
    Gasparovic, Ana Cipak
    Trougakos, Ioannis P.
    Riganti, Chiara
    [J]. DRUG RESISTANCE UPDATES, 2019, 46
  • [4] Barh D, 2010, CURR ONCOL, V17, P70
  • [5] Tamoxifen Resistance in Breast Cancer
    Chang, Minsun
    [J]. BIOMOLECULES & THERAPEUTICS, 2012, 20 (03) : 256 - 267
  • [6] Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
    Choudhary, Chunaram
    Kumar, Chanchal
    Gnad, Florian
    Nielsen, Michael L.
    Rehman, Michael
    Walther, Tobias C.
    Olsen, Jesper V.
    Mann, Matthias
    [J]. SCIENCE, 2009, 325 (5942) : 834 - 840
  • [7] Circ_0001667 knockdown blocks cancer progression and attenuates adriamycin resistance by depleting NCOA3 via releasing miR-4458 in breast cancer
    Cui, Yanfei
    Fan, Jing
    Shi, Wenbo
    Zhou, Zuozhi
    [J]. DRUG DEVELOPMENT RESEARCH, 2022, 83 (01) : 75 - 87
  • [8] BRD4 and Cancer: going beyond transcriptional regulation
    Donati, Benedetta
    Lorenzini, Eugenia
    Ciarrocchi, Alessia
    [J]. MOLECULAR CANCER, 2018, 17
  • [9] Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
    Gao, Lingyue
    Wu, Zhuo-Xun
    Assaraf, Yehuda G.
    Chen, Zhe-Sheng
    Wang, Lihui
    [J]. DRUG RESISTANCE UPDATES, 2021, 57
  • [10] Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic biomarkers for human cancers
    Garlapati, Pranavi
    Ling, Jinjie
    Chiao, Paul J.
    Fu, Jie
    [J]. CANCER CELL INTERNATIONAL, 2021, 21 (01)
12345678